Synthesis, Reactions, and Pharmacological Screening of Heterocyclic Derivatives Using Nicotinic Acid as a Natural Synthon
作者:Nehad A. Abd El-Latif、Abd El-Galil E. Amr、Alhusain A. Ibrahiem
DOI:10.1007/s00706-007-0628-z
日期:2007.6
acetate to afford 3-β-(3-indolyl)acryloylpyridine oxime and oxazole derivatives. The oxime was treated with ethyl isothiocyanate or toluene-3,5-diisocyanate in refluxing dioxane to give the corresponding ethyl thiosemicarbazide and 3,5-bissemicarbazide derivative. 3-β-(3-Indolyl)acryloylpyridine was condensed with malononitrile in refluxing ethanol in the presence of piperidine as a catalyst to give cyanoaminopyrane
Compounds containing quaternary carbons and silicon-containing groups, medical devices, and methods
申请人:Medtronic, Inc.
公开号:US20040054210A1
公开(公告)日:2004-03-18
Compounds that include diorgano groups having quaternary carbons, silicon-containing groups, and optionally urethane groups, urea groups, or combinations thereof (i.e., polyurethanes, polyureas, or polyurethane-ureas), as well as materials and methods for making such compounds.
Synthesis, Reactions, and Anti-inflammatory Activity of Heterocyclic Systems Fused to a Thiophene Moiety Using Citrazinic Acid As Synthon
作者:Abd El-Galil E. Amr、Nermien M. Sabry、Mohamed M. Abdulla
DOI:10.1007/s00706-007-0651-0
日期:2007.7
3-Aminopyrimidinone was treated with phthalicanhydride or 1,2,4,5-benzenetetracarboxylic acid dianhydride or toluene-3,5-diisocyanate to afford the corresponding imide, bis -imide, and bis -semicarbazide derivatives. The pharmacological screening showed that many of these compounds have good anti-inflammatory activity comparable to Prednisolone® as reference drug.
Release sustaining composition and sustained release preparation
申请人:Hayakawa Kazuhisa
公开号:US20050147676A1
公开(公告)日:2005-07-07
A release sustaining composition comprising a polyalkylene polyol derivative comprising repeating units U-1 derived from a water-soluble polyalkylene polyol and a polyisocyanate and repeating units U-2 derived from a dihydroxy compound and a polyisocyanate in a molar ratio of U-1/U-2 between 0.5/0.5 and 0.99/0.01 and optionally a water-soluble cellulose ether is combined with an active ingredient to make a sustained release preparation.